UC San Diego Health News

UC San Diego Health, the region’s only academic medical center, delivers world-class care and translates groundbreaking research into promising new treatments for patients.

UC San Diego Health Website

The Latest

Botox Injections May Reduce Anxiety (external site)

Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego discover that Botox injections may reduce anxiety.

Blood Thinner Found to Significantly Reduce Subsequent Heart Failure Risks (external site)

Researchers at University of California San Diego School of Medicine found using blood thinners in patients with worsening heart failure, coronary artery disease and irregular heart rhythms was associated with a reduced risk of thromboembolic events, such as stroke and heart attack.

Blanks for the Memory (external site)

UC San Diego researchers report that one kind of perceptual learning can occur in memory-impaired persons who do not actually remember what they learned.

Autism Center at UC San Diego Receives $1.5 Million Gift (external site)

The UC San Diego Autism Center for Excellence has received a $1.5 million gift from Kristin Farmer, founder and chief executive officer of ACES, a company that provides services to children with autism and their families, to support the work of Karen Pierce, co-director of the Autism Center.

Autism Diagnoses Prove Highly Stable as Early as 14 Months (external site)

Diagnoses of autism spectrum disorder (ASD) by trained professionals in children as young as 14 months are remarkably stable, suggesting that accurate screening and earlier treatment is feasible, report scientists at University of California San Diego School of Medicine.

Balance of Two Enzymes Linked to Pancreatic Cancer Survival (external site)

UC San Diego School of Medicine research sets the stage for clinicians to potentially one day use levels of a pancreatic cancer patient’s PHLPP1 and PKC enzymes as a prognostic, and for researchers to develop new therapeutic drugs that inhibit PHLPP1 and boost PKC as a means to treat the disease.